PharmaJet partners with Immunomic Therapeutics and EpiVax to develop and deliver COVID-19 Vaccine

GOLDEN, Colo. — April 14, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis® Needle-free injection system will be used to deliver a COVID-19 vaccine being developed by Immunomic Therapeutics, Inc. (ITI). ITI is a clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms using the body’s natural biochemistry to generate a broad immune response. The vaccine candidate against COVID-19 will leverage their investigational UNiversal Intracellular Targeted Expression (UNITETM) platform.